128 related articles for article (PubMed ID: 25631751)
21. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.
Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M
Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Di Lorenzo G; Autorino R; Perdonà S; De Laurentiis M; D'Armiento M; Cancello G; Mirone V; Imbimbo C; Longo N; Altieri V; Tortora G; Figg WD; De Placido S
Eur Urol; 2007 Oct; 52(4):1020-7. PubMed ID: 17360103
[TBL] [Abstract][Full Text] [Related]
23. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
James ND; Pirrie SJ; Pope AM; Barton D; Andronis L; Goranitis I; Collins S; Daunton A; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Hussain S; Russell M; Billingham LJ
JAMA Oncol; 2016 Apr; 2(4):493-9. PubMed ID: 26794729
[TBL] [Abstract][Full Text] [Related]
24. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
25. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
Nayyar R; Sharma N; Gupta NP
Int J Urol; 2009 Sep; 16(9):726-31. PubMed ID: 19769656
[TBL] [Abstract][Full Text] [Related]
27. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells.
Nogawa M; Yuasa T; Kimura S; Kuroda J; Segawa H; Sato K; Yokota A; Koizumi M; Maekawa T
Oncol Res; 2005; 15(1):1-9. PubMed ID: 15839301
[TBL] [Abstract][Full Text] [Related]
28. Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells.
Shoji K; Teishima J; Hayashi T; Ohara S; Mckeehan WL; Matsubara A
Oncol Rep; 2014 Jul; 32(1):65-70. PubMed ID: 24839986
[TBL] [Abstract][Full Text] [Related]
29. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer.
Pandya KJ; Gajra A; Warsi GM; Argonza-Aviles E; Ericson SG; Wozniak AJ
Lung Cancer; 2010 Mar; 67(3):330-8. PubMed ID: 19493585
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
[TBL] [Abstract][Full Text] [Related]
31. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
32. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
Ottewell PD; Lefley DV; Cross SS; Evans CA; Coleman RE; Holen I
Int J Cancer; 2010 Jan; 126(2):522-32. PubMed ID: 19621384
[TBL] [Abstract][Full Text] [Related]
33. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
Miyazaki H; Nishimatsu H; Kume H; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Ishikawa A; Igawa Y; Hirano Y; Homma Y
BJU Int; 2012 Dec; 110(11 Pt B):E520-5. PubMed ID: 22578070
[TBL] [Abstract][Full Text] [Related]
34. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.
Senaratne SG; Mansi JL; Colston KW
Br J Cancer; 2002 May; 86(9):1479-86. PubMed ID: 11986784
[TBL] [Abstract][Full Text] [Related]
35. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.
Brubaker KD; Brown LG; Vessella RL; Corey E
BMC Cancer; 2006 Jan; 6():15. PubMed ID: 16417633
[TBL] [Abstract][Full Text] [Related]
36. Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study.
Elsayed M; Kobayashi D; Kubota T; Matsunaga N; Murata R; Yoshizawa Y; Watanabe N; Matsuura T; Tsurudome Y; Ogino T; Ohdo S; Shimazoe T
Biol Pharm Bull; 2016 Aug; 39(8):1238-46. PubMed ID: 27181081
[TBL] [Abstract][Full Text] [Related]
37. Zoledronic acid and geranylgeraniol regulate cellular behaviour and angiogenic gene expression in human gingival fibroblasts.
Zafar S; Coates DE; Cullinan MP; Drummond BK; Milne T; Seymour GJ
J Oral Pathol Med; 2014 Oct; 43(9):711-21. PubMed ID: 24762323
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
39. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines.
Epplen R; Stöckle M; Engelmann U; Heidenreich A; Ohlmann CH
Acta Oncol; 2011 Jan; 50(1):127-33. PubMed ID: 20429730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
